Avalyn to Provide Keynote Presentation at the Formulation &
SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation...
Source: globenewswire.com
Cara Mayfield News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cara Mayfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cara Mayfield Today - Breaking & Trending Today
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and... | May 11, 2023
Source: marketscreener.com
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency - BEDFORD, Mass., May 03, 2023 --... | May 3, 2023
Source: marketscreener.com
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
16.05.2022 - - $130 Million in Non-Dilutive Capital Strengthened Financial Position - - Presentations at Upcoming ASGCT Annual Meeting Include First-Time Details of Mechanism of Action of Nuclease-Free Gene Editing Candidate HMI-103 for PKU; Symposium to ...
Source: wallstreet-online.de